A Phase I Trial: Dose Escalation of Melphalan in the “BEAM” Regimen Using Amifostine Cytoprotection  by Phillips, Gordon L. et al.
From the
Cente
Hosp
versit
Onco
Hosp
Wash
4Hem
Pharm
Memo
Cance
Financial d
Correspon
Hema
ter, Ja
tal, 6
(e-ma
Received J
 2011 Am
1083-8791
doi:10.101A Phase I Trial: Dose Escalation of Melphalan in the
‘‘BEAM’’ Regimen Using Amifostine Cytoprotection
Gordon L. Phillips, II,1 Steven H. Bernstein,1 Jane L. Liesveld,1 Camille N. Abboud,1,3
Michael W. Becker,1 Louis S. Constine,2 J. J. Ifthikharuddin,1
John E. Loughner,4 Laurie A. Milner,1 David H. Vesole,5 Jonathan W. Friedberg1With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients,
a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of mel-
phalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regi-
men before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November
2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan
dose in BEAM could be safely escalated to at least 260 mg/m2, a substantial increase from the usual dose of
140 mg/m2 in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or
dose-limiting toxicity was found. A Phase II trial is planned.
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The utility of high-dose chemotherapy (HDC) and
autologous hematopoietic stem cell transplantation
(AHSCT) for patients with selected, usually relapsed
or refractory lymphoma (both certain ‘‘aggressive’’
non-Hodgkin [NHL] andHodgkin [HL])was formally
established by randomized clinical trials over a decade
ago [1,2]; such is now a standard of care [3,4]. (The
precise role of this modality in other NHL patients is
less well defined [5].) In any case, the curability of this
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6/j.bbmt.2010.11.003rate, even in patients with ‘‘chemosensitivity’’ (ie,
greater than or equal to partial remission) to salvage
regimens; indeed, the relapse rate is so high in those
deemed ‘‘chemorefractory’’ thatHDT/AHSCT is usu-
ally not recommended [3,4].
Although there are a number of potential ap-
proaches to this problem, improving the antitumor ac-
tivity of the conditioning regimen is obvious and has
been the focus of a number of clinical trials.No strategy
has been proven to the extent that it is standard therapy
[6]. Moreover, it is likely that improvements in the pri-
mary treatment regimens [7,8] will leave smaller, more
refractory residua of relapsed lymphoma patients. Such
is suggested by results from the CORAL study; prior
exposure to rituximab had a pronounced negative
effect on post-AHSCTevent-free survival (EFS) in dif-
fuse large B-cell lymphoma (DLBCL) patients [9]. Al-
though this postulate is somewhat controversial [10],
substantial improvements to existing regimens are
required to improve upon—or arguably even main-
tain—current results.
That said, the optimal method of improving cur-
rent regimens is not known. The use of total-body ir-
radiation (TBI) does not seem helpful [11], and most
centers use chemotherapy-based regimens preferen-
tially [12]. Although the use of alternative chemother-
apy regimens [13], dose escalation of intrinsic agents
[14], and/or the addition of ‘‘newer’’ agents such as
radioimmunopharmaceuticals [15] have been tried,
each approach is potentially limited by increased toxic-
ity, notably regimen-related toxicity (RRT) [16,17].1033
1034 Biol Blood Marrow Transplant 17:1033-1042, 2011G. L. Phillips II et al.Thus, care must be undertaken with such measures to
minimize additional, especially fatal RRT that would
abrogate the gains of a reduced relapse rate. Even
lesser degrees of increased RRT may be unacceptable
if they substantially diminish quality of life and/or
increase costs.
Dose augmentation of existing agents beyond that
utilized in current HDC regimens is complicated;
although this strategy has sound theoretic grounds
[18], supportive clinical data are inconclusive [6], pos-
sibly because of the relatively minor degree by which
drug doses can be increased due to increasing RRT
[14]. The cytoprotective agent amifostine [19] may of-
fer an approach to this dilemma [20]; in a prior Phase I
trial [21], the use of amifostine permitted the safe esca-
lation of single-agent melphalan to at least 280 mg/m2,
a substantial dose increment from the standard mel-
phalan dose (without amifostine) of 200 mg/m2 in
this setting [22]. Additional analysis of the data indi-
cated significant antilymphoma activity [23]. Given
these encouraging results, and in light of the intrinsic
limitations of single-agent therapy, we sought to in-
corporate this experience into combination chemo-
therapy.
Our strategy was to modify and hopefully opti-
mize—a minor (and simpler) variant [24] of the origi-
nal [25] carmustine (BCNU), etoposide, cytarabine
(arabinosylcytosine), and melphalan (BEAM) regimen
by dose escalation of the key cytotoxic drugmelphalan,
using the cytoprotectant amifostine, in a Phase I trial.
The BEAM regimen [24,25] was chosen for a number
of reasons, including its wide utilization [12], its well-
defined and ‘‘acceptable’’ rate of RRT (mostly mucosal
barrier injury [MBI]) [24-26]), as well as our prior
experience with single-agent melphalan and amifostine
in the AHSCT setting [21,23]. A preliminary report of
this study has been published [27]; reported herein are
comprehensive results.MATERIALS AND METHODS
Study Design
When possible, recommendations involving dose
escalation studies in the situation of high-dose chemo-
therapy [28] and those involving cytoprotectants [29]
were followed.
A standard schemaof dose escalationwas used,mir-
roring our prior Phase I study [21]. Beginning at the
usualmelphalan dose in BEAM (ie, 140mg/m2) and es-
calating in fixed, 20mg/m2 increments, cohorts of 4 pa-
tients were treated. (In this report, each dose level will
be indicated by a Roman numeral with the melphalan
dose in mg/m2 following; ie, dose level VII 5 260.)
Dose escalation was allowed when none of the 4 (or
no more than 1 of 8) patients manifested severe RRT,
defined as equal to or greater than grade III [16].After completion of each cohort, entry was halted
for formal Data Safety Monitoring Board (DSMB)
and Research Subjects Review Board (RSRB) review
until all patients in the cohort passed day (D) 1100.
This produced inevitable delays in patient entry; dur-
ing the study, a total of 140 otherwise potentially eligi-
ble lymphoma patients (including 99 who received
standard BEAM without amifostine) were trans-
planted as a standard of care.
Because an evaluation of RRT was the key param-
eter measured in this study, patients who died before D
128 of causes other than RRT, and without develop-
ing gradable RRT, were deemed not evaluable for as-
sessment and replaced on a per-patient basis. All such
patients were independently and fully evaluated by the
DSMB and the RSRB before replacement with other
patients.Informed Consent
Fully documented informed consent was obtained
on all patients according to institutional guidelines, as
formulated by the RSRB.RRT Scale
The Seattle RRT scale [16] was used for a variety
of reasons, including its simplicity, clinical impact
as previously demonstrated in lymphoma patients
[17], utilization in our prior studies [21,23], and
comparability to other scales [30]. RRT was graded
weekly with a ‘‘final’’ determination at day (D) 128
for most organ systems and D 1100 for pulmonary
toxicity. (A minor issue with this scale involves grading
stomatitis as I versus II, a distinction made on the basis
of whether opioids are given by continuous intrave-
nous infusion. Because an often-utilized alternative
to continuous infusional opioid involves the use of pa-
tient-controlled analgesia (PCA), which may or may
not involve basal (ie, continuous) infusion, a distinction
between these grades could be made on this basis.
However, we believe the use of a PCA is indicated
with ‘‘more’’ rather then ‘‘less’’ stomatitis pain, and
have scored stomatitis as grade II if a PCA was used,
irrespective of the use of a basal infusion.) Organ dys-
function was considered RRT unless another obvious
etiology was found.Other Definitions
Patients who died following progression or relapse
were coded as death because of lymphoma. (Gradable
RRT after early lymphomatous progression was re-
portable in theory, but did not occur.) Death from
any other cause was considered nonrelapse mortality
(NRM). Progression-free (PFS) and overall survival
(OS) were calculated from D 10, the day of AHSCT.
Table 1. Administration Schedule
Day Time* Agent
28 Bedtime Dexamethasone 20 mg p.o.
27 0800-1000 500-1000 mL NS + 2 g Ca gluconate
27 0900 Antiemetic regimen
27 1000-1005 Amifostine dose #1 5 740 mg/m2 i.v.
27 Bedtime Dexamethasone 20 mg p.o.
26 to 22 0800 Repeat above daily, days –6 through –2
26 1020-1220 BCNU (carmustine), 300 mg/m2 i.v., 1 dose only
25 to 22 1020-1220 Etoposide 200 mg/m2 i.v. + cytarabine, 400 mg/m2, each i.v., 1 dose daily
21 0900-1000 500-1000 mL NS + 2 g Ca gluconate
21 1000 Antiemetic regimen
21 1000-1005 Amifostine dose #7 5 740 mg/m2 i.v.
21 1020-1035 Melphalan IV (140-260 mg/m2)
0 1130 (or later) AHSCT
AHSCT indicates autologous hematopoietic stem cell transplantation; p.o., orally; i.v. intravenously.
*Times could be modified as long as sequences were identical.
Table 2. Patient Characteristics
No. evaluable 28
Age, median (range) 54 (21-69)
Diagnoses
Non-Hodgkin
DLBCL (transformed) 13 (6)
MCL 3
Other 3
Hodgkin 9
Disease status
Chemosensitive 23
Other 5
No of prior regimens, median (range) 2 (1-4)
Prior local radiotherapy 13
Duration, diagnosis to AHSCT median (range) 641
Dose level
I 5 140 4
II 5 160 4
III 5 180 4
IV 5 200 4
V 5 220 4
VI 5 240 4
VII 5 260 4
CD34+ dose, 106/kg median (range) 5.87 (2.39-13.81)
AHSCT indicates autologous hematopoietic stem cell transplantation;
DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma.
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Responses were judged by International Working
Group (IWG) criteria [31]. D 1100 restaging was
used to assess disease response. Subsequent restaging
was performed as indicated by clinical events and/or
on D 1365 and yearly thereafter.
Eligibility Criteria
(1) Age 18-70 years; (2) confirmation of diagnosis
of lymphoma, either NHL or HL of any histologic
subtype [32]; (3) a history of prior standard conven-
tional primary and/or secondary (etc.) chemotherapy
and/or local radiotherapy; (4) although ‘‘chemosensi-
tivity’’ was preferred, any disease status was allowed,
except that central nervous system (CNS) involve-
ment, if present previously, was required to be in com-
plete remission (CR); (5) ECOG PS#3; (6) collection
of $2.0  106 CD341 cells/kg; (7) acceptable critical-
organ function, including left ventricular ejection
fraction of $50%, creatinine clearance $50 mL/min,
diffusing capacity for carbon monoxide $40%, and
liver function tests less than or equal to twice the
upper limits of normal; (8) absence of severe, ongoing
infection; (9) absence of another active malignancy;
(10) no evidence of pregnancy or human immunodefi-
ciency virus infection; (11) RSRB-approved informed
consent.
Stem Cell Mobilization
All patients underwent routine, successful autolo-
gous stem cell mobilization.
Regimen Administration
Manufacturer’s recommendations for the prepara-
tion and administration of amifostine were followed
[33]. All drug doses were determined using the lesser
of actual or corrected ideal body weight (corrected 5
ideal 1 25% of [actual-ideal]). Amifostine was given
daily before the first dose of chemotherapy that day;
particular attention was paid to the administration ofamifostine by 5-minute intravenous (i.v.) push, exactly
15 minutes before the chemotherapy dose was given.
Dexamethasone, antiemetics, and intravenous fluids
with calcium salts were given as previously reported
[21,23] and as indicated in Table 1. Neither cryopro-
tection [34] nor palifermin was allowed.Additional Therapy
Although not formally a part of this Phase I study,
post-AHSCT involved-field radiotherapy (IF-RT)
and/or allogeneic HSCT was utilized in selected pa-
tients. Post-relapse therapy was individualized.Supportive Care
Supportive care was given as per routine. Filgras-
tim was started on D15 at a dose of 5 mg/kg/day until
sustained absolute neutrophil count (ANC) recovery
of $0.5  109/L.
Table 3. Hematologic Recovery
Melphalan Dose Levels ANC,* D+ Platelets,† D+
Level I 5 140 10.5 (5-11) 14.5 (9-24)
Level II 5 160 11 (9-12) 12 (11-13)
Level III 5 180 11 (9-11) 11 (9-13)
Level IV 5 200 12 (5-18) 13 (12-21)
Level V 5 220 11 (10-12) 14 (11-31)
Level VI 5 260 11 (10-12) 14.5 (11-15)
Level VII 5 260 11 (10-12) 14.5 (11-15)
Totals 10 (5-18) 13 (9-31)
*Greater than or equal to 0.5  109/L, the first of 3 consecutive days.
†Greater than or equal to 20  109/L, the first of 7 consecutive days.
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Patient Characteristics
As indicated in Table 2, the median age of the 28
evaluable patients was 54 (range: 21-69) years. Diag-
noses included DLBCL in 13 (transformed from other
histologies in 6), Hodgkin lymphoma in 9, mantle cell
lymphoma (MCL) in 3, and otherNHL histologies (ie,
chronic lymphocytic leukemia/small cell lymphocytic
lymphoma (SLL), peripheral T cell lymphoma, and
marginal-zone lymphoma) in 3 other patients. All pa-
tients had been previously treated with primary and
subsequent, salvage chemotherapies after progression
or relapse (median number of regimens 2, range:
1-4). All patients with B cell NHL had previously re-
ceived rituximab, usually in multiple cycles (median
2, range: 1-4). Salvage therapy produced a state of
‘‘chemosensitivity’’ in 23, whereas 5 had lesser degrees
of response.
Patients Entered and Those Evaluable
Between the inclusive dates of 30 July 2003 and 25
November 2009, a total of 32 patients were screened,
entered, and treated, after informed consent was ob-
tained, at the dedicated facilities of Strong Memorial
Hospital, Wilmot Cancer Center, University of Ro-
chester Medical Center. Four of these patients were
later deemed not evaluable, as detailed below. All sur-
viving patients have a minimum follow-up of more
than 1 year.
Overall Outcomes
As of September 1, 2010, 9 evaluable patients were
alive without progression or relapse at median D
11551, range D 1466 to D 12065. One of these pa-
tients, PSN 07-05, received Level II 5 160 while in
a salvage chemotherapy-resistant relapse; he achieved
CR and subsequently underwent consolidative radia-
tion and later, reduced-intensity conditioning and
allogeneic stem cell transplant; 4 other patients had
post-AHSCT consolidative radiation alone.
Five patients are alive following post-AHSCT re-
lapse, including 2 whose lymphoma recurred following
subsequent allogeneic transplants, and another who is
scheduled to undergo an allograft in the near future.
Twelve other patients died after recurrence, including
2 who underwent subsequent allotransplants. Two
patients died of ‘‘late’’ NRM as discussed below.
Patients Not Evaluable
Of the 4 patients deemed not evaluable, 2 patients
were entered at dose level I 5 140, 1 at III 5 180, and
another at VI5 240. Currently, 1 is alive and well at D
1492, 1 died at D 1 792 of progression, and 2 others
died of NRM. Details of these cases are as follows: (1)
PSN 03-03 (I 5 140) developed nausea and emesisduring the regimen and withdrew consent on D 25.
Because he was being treated at the usual melphalan
dose in BEAM of 140 mg/m2, the remainder of the
regimen was given without amifostine; he had an un-
complicated recovery but eventually died because of
progression at D1792. (2) PSN 05-03 (I5 140) devel-
oped ‘‘sepsis syndrome’’ on D 110 and subsequently,
multiorgan dysfunction syndrome; death because of
this complication occurred on D 121. (3) PSN 12-
05 (III 5 180) had no early RRT and was discharged
home on D 114; he was found unconscious at home
on D 116 and died on D 118. (This case is discussed
in more detail below under ‘‘Cardiotoxicity.’’) (4) PSN
24-07 (VI 5 240) withdrew consent before receiving
the first dose of amifostine and was subsequently given
‘‘standard’’ BEAM (ie, melphalan 140 mg/m2) without
amifostine; he is alive and well at D1492. In each case,
the DSMB and RSRB independently deemed the re-
movals and/or death to be because of non-RRT causes,
and another patient was entered at that level.
Acute Amifostine Infusion Toxicity
Although a number of patients had transient symp-
toms of mild severity (eg, sneezing, flushing, nausea,
emesis, etc.) during the amifostine infusions, none re-
quired cessation of the infusion. Postchemotherapy
hypocalcemia was frequent despite routine replace-
ment, but no patient developed clinical signs of
hypocalcemia.
Stem Cell Mobilization Results
In 16 cases, mobilization was performed using fil-
grastim after the final course of salvage chemotherapy
(in 1 case, plerixafor was included). In 11 cases, a com-
bination of cyclophosphamide 2.0-3.0 g/m2 and fil-
grastim was used, and 1 case was mobilized with
filgrastim and plerixafor without chemotherapy. The
median CD341 dose infused was 5.87 (range: 2.39-
13.81)  106/kg.
Hematologic Toxicity and Recovery
All patients developed profound pancytopenia; as
indicated in Table 3, all also had prompt and sustained
hematologic recovery. There was no effect of
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For the entire group, recovery of a sustained ANC
$0.5  109/mL occurred on median D 110 (range:
15 to 118), and a sustained platelet recovery $20 
109/mL on median D 113 (range: 19 to 131). (All
not-evaluable patients had prompt hematologic recov-
eries as well.) Interestingly, 4 patients had ANC recov-
ery at either D 15 or 16; corresponding CD341 cell
doses were 5.94, 3.20, 3.38, and 6.65 106/kg, respec-
tively. Also, only 4 patients had platelet recoveries later
than D 115 and none later than D 131. No cases of
treatment-related myelodysplastic syndrome (MDS)
or acute myeloid leukemia have been observed.Nonhematologic Toxicity (ie, RRT)
As indicated in Table 4, gradable RRT was rela-
tively mild. Furthermore, no patient developed other-
wise gradable RRT between D 128 and D 1100.
Mucosal barrier injury
All patients save 1 had some evidence of MBI. No-
tably, however, no patient had either manifestation of
MBI (‘‘oral stomatitis (OS)’’ or ‘‘gastrointestinal (GI)
toxicity’’) graded in this schema that reached grade III
(ie,‘‘need for preventive intubation, aspiration pneu-
monia, noninfective ileus, or hemorrhagic enterocoli-
tis’’) [16], even at level VII 5 260. Stomatitis and
gastrointestinal toxicity occurred together in 16 cases.
No patient required total parenteral nutrition. There
was no obvious worsening MBI with the higher mel-
phalan dose levels.
Cardiotoxicity
Three patients had gradable cardiotoxicity in the
form of atrial fibrillation. Two patients (1 at IV 5
200, and 1 at VII5 260), neither with a history of car-
diac disease, and both with normal cardiac screening
studies, developed grade II cardiotoxicity (ie, atrial fi-
brillation) on D 17 and 18, respectively. Another pa-
tient (V 5 220) with a history of atrial fibrillation (butTable 4. Regimen-Related Toxicity (RRT)*
Dose Level No. Pts/Eval None MBI* (OS) MBI*
I 5 140 6/4 — I (3)
II (1)
I
I
II 5 160 4/4 — I (4) —
III 5 180 5/4 1 I (1)
II (2)
—
I
IV 5 200 4/4 — I (2)
II (2)
I
—
V 5 220 4/4 — I (1)
II (2) I
VI 5 240 5/4 — II (3) I
VII 5 260 4/4 — I (1)
II (2)
I
—
MBI indicates mucosal barrier injury; OS, oral stomatitis; GI, gastrointestinal t
*No. of patients in parentheses; note some patients had >1 RRT.who was in sinus rhythm at the beginning of therapy)
developed recurrent atrial fibrillation on D 18. In all
cases, control was achieved easily with medical therapy
alone; atrial fibrillation was not persistent or recurrent.
Two other cases bear amplification regarding pos-
sible cardiotoxicity—even if not so graded. PSN 12-05
(III5 180), a 65-year-old man with a history of severe
(yet compensated and stable) coronary artery disease
and ventricular tachyarrhythmias, previously had un-
dergone nodal ablation and pacemaker placement.
Shortly after AHSCT, he developed unstable angina
(without arrhythmias) that was treated medically; he
recovered and was discharged on D 114. He was
found unconscious at home, in asystole, on D 116.
He was successfully resuscitated but felt to have irre-
versible anoxic brain damage and was removed from
life support on D 118. Permission for an autopsy
was refused. Following a DSMB and RSRB review,
his death was deemed to be because of coronary artery
disease and not RRT.
A second patient (PSN 16-06), a 32-year-old fe-
male with no history of cardiac disease (but multiple
intrinsic risk factors for cardiovascular disease, includ-
ing obesity, hypertension, and dyslipidemia) died of an
apparent myocardial infarction while in remission and
otherwise well on D 1299. Previous therapy for
Hodgkin lymphoma had included anthracycline che-
motherapy and 2 courses of thoracic radiation.
Pulmonary toxicity
Gradable pulmonary toxicity was minimal; 2 pa-
tients (1 at III 5 180 and 1 at VII 5 260) developed
grade I RRT. Both patients developed early, unex-
plained mild hypoxia with nonspecific clinical and
radiologic findings that resolved with routine support-
ive measures that did not include corticosteroids. Al-
though 1 had an increasing pleural effusion, probably
tumor related, in neither case could pulmonary RRT
be excluded.
Notably, 1 other patient (PSN 27-08) treated at
VI 5 240 developed bronchiolitis obliterans, which(GI) Cardiac Pulmonary Hepatic Renal
(2)
(3)
— — — —
— I (1) —
(1)
I (1) — —
(3) II (1) — —
— —
(4) II (1)
(4) — I (1)
(2) II (1) I (1) — —
oxicity.
Table 5. Response and Outcome Summary
Entry Disease
Stat
Response
(d +100) No. Pts.
Alive Without
Relapse
Progression/
Relapse NRM
PIF (S)/SR CR 14 8 4 2
PIF (R)/RR CR 1 1* — —
PIF (S)/SR <CR 9 — 9 —
PIF (R)/RR <CR 4 — 4 —
Total 28 9 17 2
CR indicates complete remission; NRM, nonrelapse mortality; CR, com-
plete remission; PIF (R or S), primary induction failure (resistant or sen-
sitive); RR, resistant relapse; SR, sensitive relapse.
*This patient subsequently received an allogeneic HSCT as consolida-
tion on D+ 162.
Figure 1. Study group. (A) PFS. (B) OS.
1038 Biol Blood Marrow Transplant 17:1033-1042, 2011G. L. Phillips II et al.was not graded because of the time of onset (ie, D
1265). She survived until D 1834 free of lymphoma,
but was severely debilitated because of this complica-
tion from its onset until her death.
Hepatic toxicity
One patient (PSN 10-04) treated at II5 160 devel-
oped transient and mild (grade I) elevation of liver
function abnormalities on D 17 that resolved sponta-
neously onD110. Although we could not exclude that
this finding was because of the conditioning regimen,
it is of note that this patient had mild, unexplained,
fluctuating liver function studies before AHSCT.
Renal toxicity
One patient (PSN 25-08) treated at VI 5 240 de-
veloped transient elevation of serum creatinine (grade
I) that resolved with conservative management. We
could not exclude a contribution by the regimen.
Other toxicities
No other RRT, graded (ie, bladder or CNS) or
nongraded (ie, cutaneous, endocrine, muscle, etc.) by
this scale, were noted.
Late (ie, .D 1100) toxicities
The cases of bronchiolitis obliterans and (late)
myocardial infarction are noted above. No other late
toxicities or second malignancies have been observed.
Length of hospital stay
Admittedly an indirect parameter of overall toxic-
ity, the median duration of primary hospitalization
(ie, for AHSCT) was 20 days (range: 11-37). This du-
ration was similar to that observed in the 99 other lym-
phoma patients given ‘‘standard’’ BEAM before
AHSCT during this period (ie, median 19 days, range:
16-64). Four study patients were readmitted within 6
weeks after discharge, although none for RRT; 1 had
a central line–associated blood stream infection, 1
had deep venous thrombosis because of a central ve-
nous catheter, and 2 had complications related to early
disease progression.
Disease responses
Although determination of degree of response and
other, long-term outcome parameters were not pri-
mary goals in this Phase I study, such were of obvious
interest. Unfortunately, interpretation of these param-
eters is complicated by heterogeneity of various
disease-related and treatment-related factors (eg, the
variable melphalan doses), as well as the use of post-
transplant ‘‘consolidation’’ modalities such as in-
volved-field radiotherapy and/or (in 1 case) an
allogeneic transplant. In any case, Table 5 summarizesthese data. Overall, CRs occurred in 15/28 (54%), in-
cluding 14/23 (61%) of those judged ‘‘chemosensi-
tive’’; responses were noted at all dose levels. The
CR rate in patients deemed ‘‘chemorefractory’’ was
low: 1/5 (20%).
PFS and OS
Because only 4 patients were accrued at each dose
level, study patients at all dose levels were combined
for these analyses. As indicated in Figure 1A and 1B,
median PFS and OS were 423 (range: 55 to .2065)
Figure 2. ‘‘Control’’ group. (A) PFS. (B) OS.
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Overall probabilities of PFS and OS at 1, 3, and 5 years
were 0.54, 0.35, and 0.30 and 0.71, 0.53 and 0.53,
respectively.
As discussed above, it is difficult to identify a suit-
able control group with which to compare these data
regarding response in the context of a Phase I trial.
However, and as noted above, the substantial delays
in patient entry encountered while awaiting day
1100 evaluations for the last patient in each cohort
led to the contemporaneous treatment of 99 patients
with ‘‘standard BEAM’’ (ie, 140 mg/m2 melphalan
and no amifostine) and AHSCT. Therefore, in the in-
terest of assessing the relative efficacy of the study reg-
imen, we evaluated OS and disease-related deaths for
this contemporary cohort of ‘‘control’’ patients, nota-
bly ‘‘matched’’ by no other criteria.
As shown in Figure 2A and 2B, themedian PFS and
OS for standard BEAM patients were both 2033
(range: 37 to .2443). Also, the probabilities for DFS
at 1, 3, and 5 years were 0.67, 0.51, and 0.51; values
for OS at these intervals were 0.80, 0.67, and 0.54.
Thus, and within the constraints inevitable with the
comparison noted above, study patients appeared to
fare about as well as the ‘‘control’’ patients. A moremeaningful comparison would require a detailed anal-
ysis well beyond the scope of this Phase I study.DISCUSSION
In this study, the use of amifostine allowed safe
dose escalation of melphalan in the BEAM regimen
to at least 260 mg/m2, roughly an 85% increase of
the usual dose of 140mg/m2.No dose-limiting toxicity
or maximal tolerated dose was found. Again, it is im-
portant to emphasize the difference between this study
and most prior studies using amifostine in the high-
dose chemotherapy and AHSCT setting. Although it
is beyond the scope of this discussion to review these
studies in detail, most utilized amifostine with ‘‘con-
ventional’’ high-dose regimens [35-42], whereas this
study involved dose escalation beyond the doses used
in these regimens of the putative key cytotoxic
element of BEAM—high-dose melphalan.
At the time this study was undergoing develop-
ment, we were unsure regarding the need for ami-
fostine doses before the nonmelphalan drugs. In
consideration of this uncertainty, as well as what was
felt to be a favorable risk:benefit ratio, we decided to
administer amifostine before each agent. Subsequent
data suggest such a strategy to not be of benefit for
BCNU [41], and arguably it may not be for etoposide
and cytarabine either. Although we are now dubious
that amifostine is required for these agents, our results
reflect usage in this manner.
The postulate of significant cytoprotection of
melphalan-related RRT is based on the absence of se-
vere gradable RRT at all dose levels studied.More con-
clusive evidence is lacking; however, in our opinion, it is
not ethical to perform a trial of augmented melphalan
without cytoprotection. Moreover, although we feel
that cytoprotection was essential to this result, reduc-
tion of RRT (especially MBI) in this setting is not
unique to amifostine, as other investigators have found
that other agents such as palifermin can protect from
both oral [43] and (perhaps less convincingly)more dis-
tal gastroenterologic toxicity [44] resulting from ‘‘stan-
dard’’ high-dose TBI-containing regimens. Also, other
colleagues have reported the utility of ‘‘ice chip’’ cryo-
therapy [34] to reduce MBI with high-dose melphalan
at a dose of 200 mg/m2. Whether such would be effec-
tive in patients given augmented, high-dose chemo-
therapy regimens such as ours is untested.
Given that MBI is the chief RRT of BEAM and
AHSCT [25,26], prevention of severe MBI was critical
to the success of our study. Although an increased
frequency and severity of MBI was possible, our prior
experience with high-dose melphalan as a single agent
with amifostine was reassuring, and indeed, we did not
observe severe (ie, equal to or greater than grade III)
MBI in the current trial. Although admittedly best
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verity of MBI observed in the current study, as well as
the use of various supportive care modalities used to
treat MBI, compare favorably with the ‘‘standard’’
BEAM dose of melphalan (ie, 140 mg/m2) without
amifostine [24-26].
We also hoped that the amifostine would also pro-
tect against RRT other thanMBI; because such did not
regularly occur, this postulate remains difficult to as-
sess. In particular, we anticipated protection from
pneumonitis, a potentially severe complication of
BEAM [24,25]. Although the date of occurrence (D
1265) was well beyond the evaluation period of
D 1100 (and thus it was not formally included as
a RRT by the scale used [16]), the finding of bronchio-
litis obliterans in a single patient was very concerning.
This ominous complication is variably observed in the
allogeneic setting, especially in the presence of chronic
graft-versus-host disease (GvHD) [45], but is distinctly
unusual in the AHSCT setting [46]. Accordingly, we
cannot exclude the possibility that this complication
was because of toxicity of the study regimen; both mel-
phalan and BCNU produce lung toxicity, albeit of dif-
ferent types [47], and both pneumonitis and
pulmonary fibrosis have been reported with BEAM
[24,25]. Admittedly less likely, one could speculate
that bronchiolitis obliterans in this case was
a manifestation of autologous GvHD [48], although
the patient had no other clinical manifestations of
this process, and to our knowledge such has never
been reported. In any case, 5 other patients treated at
doses of 240-260mg/m2 and followed for longer inter-
vals have not developed bronchiolitis obliterans (or
other noninfectious pulmonary findings)—admittedly
an inadequate basis to provide assurance this was
only a chance occurrence.We will, of course, continue
to evaluate the pulmonary function studies and clinical
status of our surviving patients.
Based on our prior Phase I experience using ami-
fostine with high-dose melphalan as a single agent
[21], we anticipated possible cardiotoxicity in the
form of atrial dysrhythmias, which is a known, if rela-
tively infrequent, complication of high-dose melpha-
lan therapy (ie, 200 mg/m2) in standard AHSCT
regimens [49]. We observed 2 clear (ie, de novo) cases
of atrial fibrillation in the current study; this complica-
tion produced minimal symptomatology, and both
were converted (and controlled) with medical manage-
ment alone.
Unexpectedly, 2 patients experienced apparent
myocardial infarctions on D 116 and D 1299. Al-
though neither was deemed to be RRT, such is impos-
sible to exclude; we cannot find a report in the
literature of severe cardiotoxicity due to high-dose
melphalan [50]; these reports obviously did not use
our regimen. In any case, our findings emphasize the
need for complete cardiac evaluation pretransplant,and close posttransplant assessment as well, especially
in patients with a history of cardiac disease and/or rec-
ognized risk factors. More provocatively, one could
consider excluding patients with a history of severe
cardiac disease on future trials involving augmented
high-dose melphalan therapy.
Interestingly, it is also possible that amifostine pro-
tected and/or stimulated normal hematopoietic pre-
cursors to hasten count recovery in some patients.
The finding of rapid count recovery, notably the D
15 or 16 ANC recovery seen in 4/28 patients, con-
trasts with such rapid ANC recovery being observed
in only 4/325 other AHSCT patients similarly treated
during the same time frame (data not shown). Such an
effect should not be completely unexpected, as both
preclinical and clinical [51] data suggest this possibil-
ity—a finding that could conceivably be exploited
clinically. Also, and although amifostine has modest
favorable effects in MDS therapy [52], its role in pre-
venting therapy-related MDS is speculative.
As noted previously, it is difficult to compare our
response data to other studies, due not only to the in-
evitable patient and disease-related heterogeneity but
also to treatment heterogeneity (especially variable
doses of melphalan; only 4 patients were treated at
each dose). That said, comparison of response data is
of obvious interest, as Phase I trials such as this are
unlike ‘‘first in man’’ Phase I studies; substantial re-
sponses are anticipated with the former. In brief, our
comparison between mephalan-augmented BEAM
and standard BEAM patients indicates nomajor differ-
ences in outcomes. As before, a more detailed compar-
ison would involve a more complicated analysis or,
ideally, a randomized controlled trial.
It is also important to note that 2 elements of this
study may, at least possibly, produce opposite effects—
namely, tumor cytoprotection because of amifostine,
and increased cytoreduction with the augmented doses
of melphalan. Although neither could be addressed de-
finitively in our trial, a critical question in all cytoprotec-
tion studies is whether the cytoprotective agent might
compromise the antineoplastic effect of the regimen.
Although the bulk of existing evidence, both preclinical
and clinical [53], suggests amifostine does not have
a profound cytoprotective effect on lymphoma cells,
such cannot be excluded from our data.
The potential benefits of the dose-augmented reg-
imenwere also difficult to discern, althoughour limited
comparison indicated at least rough equivalency to
standard therapy. Also, although only 4/14 chemosen-
sitive patients who achieved CR after AHSCT on this
protocol have relapsed (at least comparable to what
one sees using the standard BEAM regimen [24,25]),
even the augmented doses of melphalan utilized in
some patients did not abrogate progression and/or
relapse (especially in ‘‘chemorefractory’’ patients),
and it seems unlikely that we are close to developing
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improved antitumor efficacy. Thus, continued attention
must be paid to known factors such as the production
of a ‘‘minimal residual disease’’ state before AHSCT
procedures, as well as various post-AHSCTmodalities
such as local irradiation [54] and perhaps immunother-
apy [55] and/or allogeneic transplantation [56].
Finally, and admittedly based on limited data, the
role of the ‘‘nonmelphalan’’ elements in BEAM may
be questioned, as results from this study at least super-
ficially resemble those from our earlier Phase I-II
study using escalated-dose melphalan as the sole anti-
neoplastic agent in another heterogenous group of
lymphoma patients [23]. If the results are indeed
comparable—and we would emphasize that available
data is inadequate for a definitive judgment—the sim-
plicity of the single agent therapy may be preferred.
Alternatively, this element could be ‘‘extracted’’ from
BEAM and used as the basis of a novel regimen using
other agents. In any case, a Phase II trial is planned us-
ing BEAMwith themelphalan dose of 260mg/m2 with
amifostine.
In summary, we have presented evidence that ami-
fostine cytoprotection is effective in the BEAM regimen
involving dose-escalated melphalan. Additional studies
may be required to optimize this regimen and/or assess
its efficacy in selected ‘‘high-risk’’ patients [56].ACKNOWLEDGMENTS
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